Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PROCEPT BioRobotics Corporation is a U.S.-based medical technology company focused on developing and commercializing robotic solutions for urology, specifically the surgical treatment of benign prostatic hyperplasia (BPH). The company operates within the medical devices and surgical robotics industries, addressing a large and growing patient population affected by lower urinary tract symptoms due to prostate enlargement.
The company’s primary revenue driver is the AQUABEAM® Robotic System, which enables Aquablation® therapy, a minimally invasive, image-guided surgical procedure for BPH. PROCEPT is positioned as a differentiated alternative to traditional BPH treatments by combining real-time imaging, robotics, and automated tissue resection. Founded in 2007, the company progressed from early clinical development through FDA clearance, completed an initial public offering in 2021, and has since focused on commercial expansion and clinical adoption.
Business Operations
PROCEPT BioRobotics generates revenue primarily through the sale and placement of its AQUABEAM® Robotic System, along with recurring revenue from single-use consumables, service contracts, and system upgrades associated with Aquablation procedures. Operations are organized around a single operating segment focused on robotic BPH therapy, with an integrated model covering research and development, manufacturing oversight, clinical support, and direct sales.
The company operates a direct commercial organization in the United States, complemented by distributor-based sales in select international markets. Core assets include proprietary robotic hardware, imaging software, and treatment planning algorithms. PROCEPT maintains clinical education and training programs for urologists and hospital systems, which are integral to driving procedural adoption and recurring utilization.
Strategic Position & Investments
Strategically, PROCEPT BioRobotics is focused on expanding the adoption of Aquablation therapy as a standard surgical option for BPH across a broader range of prostate sizes and patient profiles. Growth initiatives include increasing U.S. hospital penetration, expanding international distribution, and advancing next-generation system enhancements to improve procedural efficiency and outcomes.
The company has invested heavily in clinical trials and post-market studies to support guideline inclusion, reimbursement coverage, and physician confidence. PROCEPT does not operate as a holding company and has no material portfolio of unrelated subsidiaries; instead, investments are concentrated internally on product development, manufacturing scale, digital integration, and clinical evidence generation within the robotic urology sector.
Geographic Footprint
PROCEPT BioRobotics is headquartered in Redwood City, California, and its primary commercial presence is in North America, which represents the majority of revenue. The company has established a growing footprint in Europe, Asia-Pacific, and other select international regions through a combination of direct sales infrastructure and third-party distributors.
International operations focus on markets with established reimbursement pathways and high procedural volumes for BPH. While the United States remains the core market, international expansion is a stated strategic priority, supported by regulatory clearances and localized clinical training initiatives.
Leadership & Governance
PROCEPT BioRobotics is led by an executive team with experience in medical devices, robotics, and commercial healthcare operations. The leadership emphasizes disciplined growth, clinical evidence, and long-term value creation through technology differentiation and procedural standardization.
Key executives include:
- Rei Benjamin – President and Chief Executive Officer
- Kevin Watters – Chief Financial Officer
- Sanjeev Taneja – Chief Technology Officer
- David Kaysen – Chief Legal and Compliance Officer
- Mark B. Matz – Chief Commercial Officer
The board of directors and executive leadership collectively guide corporate strategy, capital allocation, and governance, with a focus on regulatory compliance, physician adoption, and sustained innovation in robotic-assisted urologic care.